Related Experiment Videos
Intestinal permeability to [51Cr]EDTA in children with Crohn's disease and celiac disease
1Service de Clinique Pédiatrique et Génétique Médicale, Hôpital Huriez, CHU, Lille, France.
Insights
The intestinal permeability test using chromium-51 ethylenediaminetetraacetic acid ([51Cr]EDTA) revealed increased gut permeability in children with Crohn's disease or celiac disease. This test aids in diagnosing pediatric small bowel diseases.
Area of Science:
- Gastroenterology
- Pediatric Medicine
- Diagnostic Medicine
Background:
- Intestinal permeability is a key indicator of gut health.
- Assessing small bowel disease in children can be challenging due to atypical presentations.
- Chromium-51 ethylenediaminetetraacetic acid ([51Cr]EDTA) is a well-established probe for measuring gastrointestinal permeability.
Purpose of the Study:
- To evaluate intestinal permeability in children with Crohn's disease and celiac disease using the [51Cr]EDTA test.
- To compare intestinal permeability between healthy children and pediatric patients with inflammatory bowel disease or celiac disease.
- To determine the utility of the [51Cr]EDTA permeability test in diagnosing pediatric small bowel disorders.
Main Methods:
- Oral administration of 75 kBq/kg [51Cr]EDTA to fasted healthy adults, control children, children with Crohn's disease, and children with celiac disease.
- Measurement of 24-hour urinary excretion of [51Cr]EDTA as a percentage of the total oral dose.
- Statistical analysis to compare permeability between control groups and patient groups.
Main Results:
- Mean [51Cr]EDTA urinary excretion was significantly higher in children with Crohn's disease or celiac disease (5.35 +/- 1.94%) compared to healthy control children (1.59 +/- 0.55%).
- Intestinal permeability was elevated in children with active or inactive Crohn's disease (small bowel or small bowel and colon involvement) and untreated celiac disease.
- A statistically significant difference (p < 0.001) was observed between control children and patients.
Conclusions:
- The [51Cr]EDTA permeability test effectively identifies increased intestinal permeability in children with Crohn's disease and celiac disease.
- This non-invasive test can aid in the early detection and diagnosis of small bowel diseases in pediatric patients, especially those with subtle or atypical symptoms.
- The [51Cr]EDTA test may help guide further diagnostic investigations for suspected pediatric small bowel conditions.
Abstract:
[51Cr]EDTA was used as a probe molecule to assess intestinal permeability in 7 healthy control adults, 11 control children, 17 children with Crohn's disease, and 6 children with untreated celiac disease. After subjects fasted overnight, 75 kBq/kg (= 2 microCi/kg) 51Cr-labeled EDTA was given by mouth; 24-h urinary excretion of [51 Cr]EDTA was measured and expressed as a percentage of the total oral dose. Mean and SD were as follows: control adults 1.47 +/- 0.62, control children 1.59 +/- 0.55, and patients with Crohn's disease or celiac disease 5.35 +/- 1.94. The difference between control children and patients was statistically significant (p less than 0.001). These results show that intestinal permeability to [51Cr]EDTA is increased among children with active or inactive Crohn's disease affecting small bowel only or small bowel and colon, and with untreated celiac disease. The [51Cr]EDTA permeability test could facilitate the decision to perform more extensive investigations in children suspected of small bowel disease who have atypical or poor clinical and biological symptomatology.